SCHEMBL14010

SCHEMBL14010

NCCCNCc1ccc(-c2c[nH]c(NC(=O)Nc3c(Cl)cc(Cl)cc3Cl)nc2=O)cc1F

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH2 P05091 1/20 0.35
BDKRB1 P46663 7/20 0.34
PDCD1LG2 Q9BQ51 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
CHEK1 O14757 2/20 0.33
GRK5 P34947 1/20 0.33
PDE4B Q07343 3/20 0.32
IGF1R P08069 1/20 0.31
GCGR P47871 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
GCG P01275 1/20 0.31
RET P07949 1/20 0.31
KDR P35968 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17354271 0.94 PDCD1LG2 (0.34) ALDH2BDKRB1PDCD1LG2CD274CHEK1
SCHEMBL13618 0.93 ALDH2 (0.40) ALDH2BDKRB1PDCD1LG2CD274CHEK1
SCHEMBL14161 0.92 CNR1 (0.35) ALDH2BDKRB1PDCD1LG2CD274CHEK1
SCHEMBL13805 0.90 GCGR (0.36) ALDH2PDCD1LG2CD274GRK5GCGR
SCHEMBL14850233 0.90 RET (0.32) ALDH2BDKRB1PDCD1LG2CD274CA12
SCHEMBL14149 0.89 ROCK2 (0.40) ALDH2BDKRB1GCGRGCG
SCHEMBL13729 0.89 KMT2A (0.36) ALDH2BDKRB1PDCD1LG2CD274CHEK1
SCHEMBL13789 0.88 ALDH2 (0.35) ALDH2BDKRB1PDCD1LG2CD274CHEK1
SCHEMBL13669 0.88 CNR1 (0.45) ALDH2CHEK1GCGRGCG
SCHEMBL13703 0.88 LYN (0.39) BDKRB1GRK5IGF1RGCGRCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9845297-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2017-12-19 US disclosed
US-9845297-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2017-12-19 US disclosed
US-20160031828-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME SILICON VALLEY BANK 2016-02-04 US disclosed
US-20160031828-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME SILICON VALLEY BANK 2016-02-04 US disclosed
US-9216979-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-12-22 US disclosed
US-9216979-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-12-22 US disclosed
US-20130090326-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2013-04-11 US disclosed
US-20130090326-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2013-04-11 US disclosed
WO-2011047323-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090326-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT ALDH2 611/4885BDKRB1 3258/4885PDCD1LG2 3978/4885
US-20160031828-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT ALDH2 611/4885BDKRB1 3258/4885PDCD1LG2 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.